Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S.
Jun 20, 2024 · Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM. It proactively corrects for highs and protects against lows with insulin dosing. The waterproof device features mobile app control for ease of use. Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 earlier this year.
Dexcom announces direct-to-watch feature for G7 CGM
Mar 5, 2024 · The ONE+ system, featuring a sensor, reader, smartphone, smartwatch and applicator. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year.
Insulet data shows Omnipod 5's superiority to regular pump therapy
Mar 8, 2024 · Results demonstrated significantly lower mean glucose and time above 180 mg/dL in the Omnipod 5 group. That group also spent significantly less time below 70 mg/dL. Mean time decreased from 1.66% to 1.18% with Omnipod 5, compared to an increase from 1.66% to 1.75% in the control group. Time below 54 mg/dL proved non-inferior between groups.
The 9 largest diabetes technology companies in the world
Aug 21, 2024 · 1. Abbott Diabetes Care — 2023 revenue: $5.761B. Abbott, one of the world’s largest medtech companies in a broader sense, takes the top spot in diabetes, too. The company’s Diabetes Care unit brought in more than $2 billion more than any other company on this list. With its Diabetes Care unit located in Alameda, California, Abbott ...
FDA clears iPhone app for the Insulet Omnipod 5 - Drug Delivery …
Oct 23, 2023 · Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet] Insulet (Nasdaq:PODD) announced today that the FDA granted 510(k) clearance for its Omnipod 5 App for iPhone. Clearance makes Insulet the only company offering a tubeless, automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone.
FDA approves next-gen drug delivery system from Medtronic
October 10, 2023 By Sean Whooley. The SynchroMed III system. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system. The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity.
The company behind Narcan looks toward a treatment for fentanyl ...
Mar 13, 2018 · A nasal spray designed to reverse opioid overdoses called Narcan has become a life-saving tool used by police departments and communities around the country. Now, the company that created Narcan – Opiant Pharmaceuticals (NSDQ: OPNT) – is hoping that its latest drug-device combination can help people who are overdosing from fentanyl.
FDA tentatively approves first generic version of Symbicort …
Mar 8, 2021 · Viatris (NSDQ:VTRS) and Kindeva Drug Delivery announced today that the FDA granted tentative approval of the first generic version of Symbicort.. Symbicort, an inhalation aerosol is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). The drug had U.S. branded sales of $3.5 billion for the 12 months ended January 2021, according to IQVIA.
Beta Bionics earns pharmacy benefit win for bionic pancreas
Nov 15, 2023 · Beta Bionics announced that Express Scripts added its iLet bionic pancreas and associated supplies to its commercial national formulary offerings. The decision enables faster and easier access to iLet for eligible users with plans that cover the system under their pharmacy benefit. It marks more good news for Beta Bionics, which closed a $100 ...
FDA clears Dexcom G7 next-gen CGM - Drug Delivery Business
Dec 8, 2022 · Dexcom (Nasdaq:DXCM) announced today that the FDA cleared the next-generation Dexcom G7 continuous glucose monitoring (CGM) system. FDA clearance for the highly anticipated device covers people with all types of diabetes aged 2 years and older. San Diego-based Dexcom’s device features a 60% size reduction from the previous generation, the G6.